Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Choosing the best type of credit card for rewards can enhance your spending. Learn about different cards to find the one that fits your needs.
23,104 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
AI is reshaping markets faster than many investors expect. This no-brainer artificial intelligence (AI) stock story b...
President Trump issues an emergency payroll directive for TSA workers as the DHS shutdown drags on, hoping to relieve...
Finance of America reported a profitable first quarter, reversing Q4 losses as originations climbed and portfolio gai...
Coinbase soared about 12% in trading after Sen. Lummis announced a bipartisan deal on the Clarity Act for stablecoin ...
Oil markets are in flux, and Occidental faces a pivotal year. This guide breaks down what to expect from occidental (...
Nearly half of U.S. homeowners paused moving plans in the last year, a sign that housing market inertia grows even as...
Uber’s first-quarter results sparked a rare split on Wall Street: Goldman Sachs trims the stock target, while Piper S...
A notable move in a clean energy ETF raised questions: does a big sale signal trouble or discipline in a fast-growing...
Unlock the meaning behind the natr 2026 earnings transcript. Learn how to parse numbers, gauge management guidance, a...
Analysts issued fresh upgrades on a slate of big-name stocks as earnings season continues. Applied Materials, Devon E...
A focused look at a standout semiconductor stock riding the AI wave. Learn what makes it different, how to evaluate i...